In vitro and in vivo activity of a novel antifungal small molecule against Candida infections

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Wong, Sarah Sze Wah ^a   Kao, Richard Yi Tsun ^a   Yuen, Kwok Yong ^a   Wang, Yu ^b   Yang, Dan ^a   Samaranayake, Lakshman Perera ^a   Seneviratne, Chaminda Jayampath ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; CASPOFUNGIN; FLUCONAZOLE; KETOCONAZOLE; NYSTATIN; SM 21; UNCLASSIFIED DRUG; ANILINE DERIVATIVE; CATION; FUNGAL PROTEIN; GREEN FLUORESCENT PROTEIN; HWP1 PROTEIN, CANDIDA ALBICANS; MEMBRANE PROTEIN; MOLECULAR LIBRARY; SM21 COMPOUND;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFUNGAL ACTIVITY; ARTICLE; CELL MEMBRANE PERMEABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SCREENING; DRUG STRUCTURE; FUNGAL CELL; FUNGAL STRAIN; FUNGUS ISOLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INVASIVE CANDIDIASIS; MALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; THRUSH; ANIMAL; C57BL MOUSE; CANDIDA ALBICANS; CANDIDIASIS; CELL CULTURE; CELL LINE; CHEMICAL STRUCTURE; CHEMISTRY; CONFOCAL MICROSCOPY; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; GENE EXPRESSION; GENETICS; HOST PATHOGEN INTERACTION; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MOLECULAR LIBRARY; PHARMACOLOGY; PHYSIOLOGY; PROCEDURES; PROMOTER REGION;

ANILINE COMPOUNDS; ANIMALS; ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CANDIDIASIS; CELL LINE; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; FUNGAL PROTEINS; GENE EXPRESSION; GREEN FLUORESCENT PROTEINS; HOST-PATHOGEN INTERACTIONS; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MICROBIAL SENSITIVITY TESTS; MICROSCOPY, CONFOCAL; MOLECULAR STRUCTURE; ONIUM COMPOUNDS; PROMOTER REGIONS, GENETIC; SMALL MOLECULE LIBRARIES;

EID: 84899886949     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0085836     Document Type: Article

References (58)

1. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, et al. (2004) Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 39: 309-317.
2. Odds FC (1988) Candida and candidosis: a review and bibliography. Bailliere Tindall.
3. Webb BC, Thomas CJ, Willcox MD, Harty DW, Knox KW (1998) Candida-associated denture stomatitis. Aetiology and management: a review. Part 2. Oral diseases caused by Candida species. Australian dental journal 43: 160-166. (Pubitemid 128519626)
4. Akpan A, Morgan R (2002) Oral candidiasis. Postgraduate medical journal 78: 455-459. (Pubitemid 34948150)
5. Douglas LJ (2003) Candida biofilms and their role in infection. Trends in microbiology 11: 30-36.
6. Gendreau L, Loewy ZG (2011) Epidemiology and etiology of denture stomatitis. Journal of Prosthodontics 20: 251-260.
7. Calderone RA, Fonzi WA (2001) Virulence factors of Candida albicans. Trends in microbiology 9: 327-335. (Pubitemid 32575277)
8. Sudbery PE (2011) Growth of Candida albicans hyphae. Nature reviews Microbiology 9: 737-748.
9. Ramage G, Tomsett K, Wickes BL, Lopez-Ribot JL, Redding SW (2004) Denture stomatitis: a role for Candida biofilms. Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics 98: 53-59. (Pubitemid 38953831)
10. Seneviratne CJ, Jin L, Samaranayake LP (2008) Biofilm lifestyle of Candida: a mini review. Oral diseases 14: 582-590.
11. Eggimann P, Garbino J, Pittet D (2003) Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. The Lancet infectious diseases 3: 685-702. (Pubitemid 37345347)
12. Ortega M, Marco F, Soriano A, Almela M, Martínez JA, et al. (2011) Candida species bloodstream infection: epidemiology and outcome in a single institution from 1991 to 2008. Journal of Hospital Infection 77: 157-161.
13. Pfaller MA, Diekema DJ (2007) Epidemiology of invasive candidiasis: a persistent public health problem. Clinical microbiology reviews 20: 133-163. (Pubitemid 46167771)
14. Sardi JC, Scorzoni L, Bernardi T, Fusco-Almeida AM, Mendes Giannini MJ (2013) Candida species: current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options. Journal of medical microbiology 62: 10-24.
15. Pfaller MA, Moet GJ, Messer SA, Jones RN, Castanheira M (2011) Candida bloodstream infections: comparison of species distributions and antifungal resistance patterns in community-onset and nosocomial isolates in the SENTRY Antimicrobial Surveillance Program, 2008-2009. Antimicrobial agents and chemotherapy 55: 561-566.
16. Silva S, Negri M, Henriques M, Oliveira R, Williams DW, et al. (2012) Candida glabrata, Candida parapsilosis and Candida tropicalis: biology, epidemiology, pathogenicity and antifungal resistance. FEMS microbiology reviews 36: 288-305.
17. Ostrosky-Zeichner L, Casadevall A, Galgiani JN, Odds FC, Rex JH (2010) An insight into the antifungal pipeline: selected new molecules and beyond. Nature reviews Drug discovery 9: 719-727.
18. Pfaller MA (2012) Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. The American journal of medicine 125: S3-13.
19. Sanglard D, Coste A, Ferrari S (2009) Antifungal drug resistance mechanisms in fungal pathogens from the perspective of transcriptional gene regulation. FEMS yeast research 9: 1029-1050.
20. Chandrasekar P (2011) Management of invasive fungal infections: a role for polyenes. Journal of Antimicrobial Chemotherapy 66: 457-465.
21. Siikala E, Rautemaa R, Richardson M, Saxen H, Bowyer P, et al. (2010) Persistent Candida albicans colonization and molecular mechanisms of azole resistance in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) patients. Journal of Antimicrobial Chemotherapy 65: 2505-2513.
22. Kanafani ZA, Perfect JR (2008) Antimicrobial resistance: resistance to antifungal agents: mechanisms and clinical impact. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 46: 120-128.
23. Ben-Ami R, Garcia-Effron G, Lewis RE, Gamarra S, Leventakos K, et al. (2011) Fitness and virulence costs of Candida albicans FKS1 hot spot mutations associated with echinocandin resistance. Journal of Infectious Diseases 204: 626-635.
24. Clancy CJ, Nguyen MH (2011) At what cost echinocandin resistance? Journal of Infectious Diseases 204: 499-501.
25. Seneviratne CJ, Wong SS, Yuen KY, Meurman JH, Parnanen P, et al. (2011) Antifungal susceptibility and virulence attributes of bloodstream isolates of Candida from Hong Kong and Finland. Mycopathologia 172: 389-395.
26. Hakki M, Staab JF, Marr KA (2006) Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy. Antimicrobial agents and chemotherapy 50: 2522-2524. (Pubitemid 43993195)
27. Persidis A (1999) Antibacterial and antifungal drug discovery. Nature biotechnology 17: 1141-1142.
28. Kao RY, Tsui WHW, Lee TSW, Tanner JA, Watt RM, et al. (2004) Identification of novel small-molecule inhibitors of severe acute respiratory syndrome-associated coronavirus by chemical genetics. Chemistry & biology 11: 1293-1299. (Pubitemid 39282803)
29. Toenjes KA, Munsee SM, Ibrahim AS, Jeffrey R, Edwards JE, Jr., et al. (2005) Small-molecule inhibitors of the budded-to-hyphal-form transition in the pathogenic yeast Candida albicans. Antimicrobial agents and chemotherapy 49: 963-972. (Pubitemid 40327711)
30. Lee KL, Buckley HR, Campbell CC (1975) An amino acid liquid synthetic medium for the development of mycelial and yeast forms of Candida albicans. Sabouraudia 13: 148-153.
31. John H. Rex MAG (2008) Reference method for broth dilution antifungal susceptibility testing of yeasts; Approved standard - third edition. Clinical and Laboratory Standards Institute document M27-A3 28.
32. Jin Y, Yip HK, Samaranayake YH, Yau JY, Samaranayake LP (2003) Biofilmforming ability of Candida albicans is unlikely to contribute to high levels of oral yeast carriage in cases of human immunodeficiency virus infection. Journal of clinical microbiology 41: 2961-2967. (Pubitemid 36842285)
33. da Silva WJ, Seneviratne J, Parahitiyawa N, Rosa EA, Samaranayake LP, et al. (2008) Improvement of XTT assay performance for studies involving Candida albicans biofilms. Brazilian dental journal 19: 364-369.
34. Ellepola AN, Samaranayake LP (1998) Adhesion of oral Candida albicans isolates to denture acrylic following limited exposure to antifungal agents. Arch Oral Biol 43: 999-1007. (Pubitemid 28551248)
35. Chandra J, Mukherjee PK, Leidich SD, Faddoul FF, Hoyer LL, et al. (2001) Antifungal resistance of candidal biofilms formed on denture acrylic in vitro. J Dent Res 80: 903-908. (Pubitemid 32477425)
36. Jin Y, Samaranayake LP, Samaranayake Y, Yip HK (2004) Biofilm formation of Candida albicans is variably affected by saliva and dietary sugars. Arch Oral Biol 49: 789-798. (Pubitemid 39081809)
37. Jarosz LM, Krom BP (2011) Rapid screening method for compounds that affect the growth and germination of Candida albicans, using a real-time PCR thermocycler. Applied and environmental microbiology 77: 8193-8196.
38. Miyazaki M, Horii T, Hata K, Watanabe NA, Nakamoto K, et al. (2011) In vitro activity of E1210, a novel antifungal, against clinically important yeasts and molds. Antimicrobial agents and chemotherapy 55: 4652-4658.
39. Lionakis MS, Lim JK, Lee CC, Murphy PM (2011) Organ-specific innate immune responses in a mouse model of invasive candidiasis. Journal of innate immunity 3: 180-199.
40. Takakura N, Sato Y, Ishibashi H, Oshima H, Uchida K, et al. (2003) A novel murine model of oral candidiasis with local symptoms characteristic of oral thrush. Microbiology and immunology 47: 321-326. (Pubitemid 36604617)
41. Kamagata-Kiyoura Y, Abe S, Yamaguchi H, Nitta T (2004) Protective effects of human saliva on experimental murine oral candidiasis. Journal of infection and chemotherapy: official journal of the Japan Society of Chemotherapy 10: 253-255.
42. Ramani R, Ramani A, Wong SJ (1997) Rapid flow cytometric susceptibility testing of Candida albicans. Journal of clinical microbiology 35: 2320-2324. (Pubitemid 27349804)
43. Ali I, Khan FG, Suri KA, Gupta BD, Satti NK, et al. (2010) In vitro antifungal activity of hydroxychavicol isolated from Piper betle L. Annals of clinical microbiology and antimicrobials 9: 7.
44. Toenjes KA, Stark BC, Brooks KM, Johnson DI (2009) Inhibitors of cellular signalling are cytotoxic or block the budded-to-hyphal transition in the pathogenic yeast Candida albicans. Journal of medical microbiology 58: 779-790.
45. LaFleur MD, Lucumi E, Napper AD, Diamond SL, Lewis K (2011) Novel high-throughput screen against Candida albicans identifies antifungal potentiators and agents effective against biofilms. J Antimicrob Chemother 66: 820-826.
46. Midkiff J, Borochoff-Porte N, White D, Johnson DI (2011) Small molecule inhibitors of the Candida albicans budded-to-hyphal transition act through multiple signaling pathways. PloS one 6: e25395.
47. Grald A, Yargosz P, Case S, Shea K, Johnson DI (2012) Small-molecule inhibitors of biofilm formation in laboratory and clinical isolates of Candida albicans. Journal of medical microbiology 61: 109-114.
48. Lo HJ, Kohler JR, DiDomenico B, Loebenberg D, Cacciapuoti A, et al. (1997) Nonfilamentous C. albicans mutants are avirulent. Cell 90: 939-949. (Pubitemid 27381632)
49. Odds FC, Cockayne A, Hayward J, Abbott AB (1985) Effects of imidazole- and triazole-derivative antifungal compounds on the growth and morphological development of Candida albicans hyphae. J Gen Microbiol 131: 2581-2589. (Pubitemid 16225616)
50. Hawser S, Islam K (1999) Comparisons of the effects of fungicidal and fungistatic antifungal agents on the morphogenetic transformation of Candida albicans. J Antimicrob Chemother 43: 411-413. (Pubitemid 29121883)
51. Rex JH, Pfaller MA, Rinaldi MG, Polak A, Galgiani JN (1993) Antifungal susceptibility testing. Clinical microbiology reviews 6: 367-381. (Pubitemid 23306592)
52. Ostrosky-Zeichner L, Marr KA, Rex JH, Cohen SH (2003) Amphotericin B: time for a new "gold standard". Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 37: 415-425.
53. Chandra J, Kuhn DM, Mukherjee PK, Hoyer LL, McCormick T, et al. (2001) Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance. Journal of bacteriology 183: 5385-5394. (Pubitemid 32802612)
54. Krcmery V, Kalavsky E (2007) Antifungal drug discovery, six new molecules patented after 10 years of feast: why do we need new patented drugs apart from new strategies? Recent patents on anti-infective drug discovery 2: 182-187. (Pubitemid 350200272)
55. Louie A, Drusano GL, Banerjee P, Liu QF, Liu W, et al. (1998) Pharmacodynamics of fluconazole in a murine model of systemic candidiasis. Antimicrobial agents and chemotherapy 42: 1105-1109. (Pubitemid 28227905)
56. Van't Wout JW, Mattie H, van Furth R (1989) Comparison of the efficacies of amphotericin B, fluconazole, and itraconazole against a systemic Candida albicans infection in normal and neutropenic mice. Antimicrobial agents and chemotherapy 33: 147-151. (Pubitemid 19053848)
57. Ikeda F, Wakai Y, Matsumoto S, Maki K, Watabe E, et al. (2000) Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis. Antimicrobial agents and chemotherapy 44: 614-618. (Pubitemid 30117950)
58. Andes D, Craig WA (2002) Animal model pharmacokinetics and pharmacodynamics: a critical review. International journal of antimicrobial agents 19: 261-268. (Pubitemid 34308974)